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Abstract
Purpose There is a large body of evidence supporting the
efficacy of low-level laser therapy (LLLT), more recently
termed photobiomodulation (PBM) for the management of
oral mucositis (OM) in patients undergoing radiotherapy for
head and neck cancer (HNC). Recent advances in PBM tech-
nology, together with a better understanding of mechanisms
involved and dosimetric parameters may lead to the manage-
ment of a broader range of complications associated with
HNC treatment. This could enhance patient adherence to can-
cer therapy, and improve quality of life and treatment out-
comes. The mechanisms of action, dosimetric, and safety
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considerations for PBM have been reviewed in part 1.
Part 2 discusses the head and neck treatment side effects
for which PBM may prove to be effective. In addition,
PBM parameters for each of these complications are sug-
gested and future research directions are discussed.
Methods Narrative review and presentation of PBM parame-
ters are based on current evidence and expert opinion.
Results PBM may have potential applications in the manage-
ment of a broad range of side effects of (chemo)radiation
therapy (CRT) in patients being treated for HNC. For OM
management, optimal PBM parameters identified were as fol-
lows: wavelength, typically between 633 and 685 nm or 780–
830 nm; energy density, laser or light-emitting diode (LED)
output between 10 and 150 mW; dose, 2–3 J (J/cm2), and no
more than 6 J/cm2 on the tissue surface treated; treatment
schedule, two to three times a week up to daily; emission
type, pulsed (<100 Hz); and route of delivery, intraorally
and/or transcutaneously. To facilitate further studies, we pro-
pose potentially effective PBM parameters for prophylactic
and therapeutic use in supportive care for dermatitis, dyspha-
gia, dry mouth, dysgeusia, trismus, necrosis, lymphedema,
and voice/speech alterations.
Conclusion PBM may have a role in supportive care for a
broad range of complications associated with the treatment
of HNC with CRT. The suggested PBM irradiation and dosi-
metric parameters, which are potentially effective for these
complications, are intended to provide guidance for well-
designed future studies. It is imperative that such studies in-
clude elucidating the effects of PBM on oncology treatment
outcomes.
Keywords Low-level laser therapy . Low-level light therapy .
Photobiomodulation .Mucositis . Orofacial complications .
Chemotherapy . Radiation therapy . Head and neck cancer .
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Introduction
Nearly all patients with advanced head and neck cancer
(HNC) suffer orofacial, oropharyngeal, and neck complica-
tions from treatment with radiation therapy (RT) or chemora-
diotherapy (CRT) [1].
The severity of complications varies depending upon the type
and site of the tumor, mode and intensity of therapies involved,
and individual patient characteristics. Nevertheless, in most pa-
tients, complications are associated with significant morbidity
and mortality resulting in increased use of health-care resources
and may compromise patient adherence to cancer therapy proto-
cols resulting in suboptimal outcomes. Most patients develop
multiple complications, which result in a significant burden of
illness with negative impact on quality of life (QoL) [1–5].
Supportive care addressing these complications must con-
tinue from initial diagnosis of HNC, through treatment and
survival. However, many interventions have limitations and
are primarily palliative in nature [6].
Among the presently available supportive care measures,
the use of photobiostimulation (PBM) has shown significant
promise. PBM refers to various light energies such as low-
level laser therapy (LLLT) and light-emitting diode (LED) and
visible light (see part 1).
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Systematic reviews have suggested efficacy of PBM for
oral mucositis (OM) management in myeloablative hemato-
poietic stem cell transplant (HSCT) recipients and in HNC
patients [7–12]. However, recent advances in PBM applica-
tion and PBM devices, together with a better understanding of
the pathobiology of HNC treatment-induced complications,
may lead to a broader range of indications for PBM in the
management of these problems.
A task force consisting of an international multidisci-
plinary panel of clinicians and researchers with expertise
in the area of supportive care in cancer and/or PBM
clinical application and dosimetry was formed. The mis-
sion of this group is to identify potential indications for
PBM in the management of side effects of cancer ther-
apy, design of PBM study protocols, identify validated
outcome measures, and test the efficacy and safety of
proposed protocols for the management of complications
related to cancer therapy.
Part 1 of this review addressed mechanisms of action, do-
simetric, and safety considerations. This paper (part 2) dis-
cusses the following: (i) selected oral, oropharyngeal, facial,
and neck complications of treatment for HNC, in which PBM
may have potential for prophylaxis and/or treatment; (ii) PBM
parameters for prophylaxis and therapy to mitigate these com-
plications based on current evidence and knowledge; and (iii)
directions of future research related to the use of PBM in
HNC.
PBM for the management of orofacial and neck
complications of cancer therapy
The following paragraphs summarize selected acute and
chronic complications associated with HNC therapy and the
literature relevant to the use of PBM for the management of
these complications.
For each of these complication, we propose prophylactic
and therapeutic PBM protocols based on evidence derived
from the literature and expert opinion (Table 1). These proto-
cols are intended to provide clinical guidance and to serve as a
starting point for continuing research. Please see part 1 of this
review for discussion of mechanism of action and of safety of
PBM.
Oral mucositis
Oral mucositis affects virtually all patients undergoing CRT
for HNC. Clinically, the manifestations of OM form a contin-
uum, with erythematous mucosal changes when mild, and,
ulcerative lesions that expose the submucosa when severe.
The detrimental effects of OM uponQoL and functional status
are significant [2].
The current understanding of the pathogenesis of OM is
largely based on animal models, which document the multi-
factorial nature of this inflammatory condition and have im-
plicated a cascade of interrelated events in multiple tissue
compartments. These observations lead to the five-phase
model of OM, based on the sequence of events following
cytotoxic treatment [13]. Inflammation induced by the forma-
tion of excessive reactive oxygen species (ROS) and activa-
tion of nuclear factor kappa B (NF-κB) are the key factors in
its pathobiology [14]. Subsequent studies implicated micro-
vascular injury, formation of proinflammatory cytokines,
host–microbiome interactions, and extracellular matrix alter-
ations in mucositis pathogenesis [15]. In addition, epidermal
growth factor receptor (EGFR) inhibitors and tyrosine kinase
receptor inhibitors (TKI) administered as single drugs or com-
bined with CRT may enhance OM or cause additional symp-
toms [16, 17]. Effective management options for OM are lim-
ited [18], and pain control is typically inadequate [2].
A Cochrane meta-analysis concluded that PBM may pre-
vent severe OM [7]. A systematic review and meta-analysis of
11 randomized controlled trials (RCTs) in HNC patients treat-
ed with (chemo)radiation therapy concluded that there was
consistent evidence that PBM applied with doses of 1–6 J
per point reduced OM prevalence, severity, and duration,
and its associated pain [9]. Another meta-analysis including
RCTs in various cancer treatment settings showed that PBM
reduced OM risk and decreased its severity and duration [10].
The efficacy appeared to be similar for red [630–670 nm] and
NIR (780–830 nm) light, although the optimal doses may vary
between these wavelengths. Similarly, a systematic review
and meta-analysis including 18 RCTs reported that prophylac-
tic PBM reduced severe OM and associated pain in patients
treated for HNC or undergoing HSCT [12]. The Clinical
Practice Guidelines of the Multinational Association of
Supportive Care in Cancer and International Society for Oral
Oncology (MASCC/ISOO) Mucositis Study Group found ev-
idence to recommend PBM for the prevention of OM in
HSCT recipients conditioned with high-dose chemotherapy,
with or without total body irradiation, and to suggest a role for
patients treated with RT for HNC [11, 18]. Evidence was
derived from high-quality studies using specific PBM param-
eters, and the authors noted that there remains a need to iden-
tify optimal PBM parameters per cancer treatment modality.
Based on this evidence and on our experience, we propose
the following regimen for the management of OM and muco-
sitis affecting the oropharynx: wavelength of 633–685 or 780–
830 nm; power output of between 10 and 150mW; energy
density 2–3 J/cm2, and no more than 6 J/cm2 on the tissue
surface treated; administered two to three times a week up to
daily; and using successive intraoral applications on single
spots on the mucosa, rather than a scanning motion over the
entire mucosal surface. The upper safety limit was set as a
precaution since no clinical data defining a safe upper limit
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Table 1 Suggested photobiomodulation regimens for prevention and/or treatment of cancer therapy-induced morbidity in head and neck cancer
patients
Complicaon Treatment protocol** Treatment area PBM Device 
Characteriscs and 
applicaon
Therapeuc PBM Dose Oponal target ssues
Oral Mucosis Prophylacc: 
Chemotherapy: Protocols vary.
Start PBM treatment at ﬁrst day 
of CT or prior to therapy and 
connue during all courses of 
chemotherapy
Radiotherapy: start PBM 
treatment the ﬁrst day of RT or 
prior to RT and connue during all 
days of RT (no requirement 
regarding the ming of PBM
sessions, before of aer RT
session) 
Therapeuc:
Connue treatment at least 3 
mes a week unl symptoms 
improve 
Daily treatment is recommended 
in case of severe mucosis
Extra-oral:
Infrared (IR) LED cluster 
or 
Mixed Red and IR LED 
cluster 20mW/cm2 -
80mW/cm2
Intra-oral:
630 - 830nm 
20mW - 80mW 
Extra-oral:
3 J/cm2 IR LED cluster
Intra-oral:
Prophylacc: 2 J per point 
Therapeuc: 4 J per point  
unl the whole area 
involved is covered
(2 J for prophylacc use)
Extra-oral:
Lips, cutaneous surface 
corresponding to the buccal 
mucosae, bilateral cervical 
lymphac chain*
Intra-oral:
Prophylacc: treat each of the 
at risk mucosal surfaces *
Therapeuc: sites vary, 
depending upon the site of 
mucosis
Radiaon 
dermas
Prophylacc: 
Start daily PBM treatment at the 
iniaon of RT, or with a grade 1 
radiaon dermas
Therapeuc:
Connue treatment at least 3 
mes a week unl symptoms 
improve 
Extra-oral:
Red laser diodes cluster, 
630-680 nm, 
20-150 mW/cm2
or
Mixed Red and IR LED 
cluster 20mW/cm2 -
80mW/cm2
Extra-oral:
Prophylacc: 2 J/cm2 for 
laser diodes panel,
3 J/cm2 for extra oral LED 
Cluster
Therapeuc:
At least 4 J/cm2
Extra-oral:
Cutaneous surfaces on the 
radiaon ﬁeld where dermas 
is ancipated (oen 
erythematous aer RT)
Dysphagia Prophylacc: 
Radiotherapy: start treatment the 
ﬁrst day of radiotherapy and 
connue all days of radiaon (no 
requirement regarding the 
meing of laser sessions, before 
of aer radiaon session) 
Therapeuc:
Connue treatment at least 3 
mes a week unl symptoms 
improve 
Extra-oral:
Lateral and ventral 
pharynx and larynx
Intraoral:
Soft palate, oropharynx
Extra-oral:
IR laser diodes or LED 
cluster 
750- 830 nm
20mW/cm2 - 80mW/cm2
Intra-oral:
630 - 680nm 
20mW - 150mW 
Extra-oral:
Prophylacc: 3 J/cm2 laser 
diodes or LED cluster
Intra-oral:
Prophylacc: 3 J per point 
Extra-oral:
Midline neck and lateral neck 
anterior to sternocleidomastoid 
muscle
Intra-oral:
Bilaterally, 4 points to so 
palate and onto oropharynx
Hyposalivaon
and xerostomia
Prophylacc: 
Radiotherapy: start PBM 
treatment the ﬁrst day of RT and 
connue daily with radiaon (no 
requirement regarding the ming
of PBM sessions, before of aer 
RT session) 
Extra-oral:
IR laser diodes or LED 
cluster 
750- 830 nm
20mW/cm2 - 80mW/cm2
Intra-oral:
630 - 680nm 
20mW - 150mW
Extra-oral:
Prophylacc: 3 J/cm2 laser 
diodes or LED cluster
Intra-oral:
Prophylacc: 3 J/cm2 per 
point
Extra-oral:
Major salivary glands, 
bilaterally (parod, sublingual 
and submandibular)*
Intra-oral:
Total of 6 points (3 each side) 
targeng major salivary glands 
and minor salivary glands (on 
vesbular side, in the rear of 
salivary ducts)
Dysgeusia Therapeuc:
Connue treatment from the day 
the paent complains of taste 
alteraons, at least 2 or 3 mes a 
week unl symptoms improve**
Intra-oral:
630 - 680nm 
20mW - 150mW 
Intra-oral:
Dorsal and lateral tongue at 
3 J/cm2
Intra-oral:
A total of 10 points on the 
dorsum of the tongue 
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are currently available. Emission type, continuous or pulsed
(<100 Hz) as low-frequency pulsed light may be superior to
continuous wave light for wound healing or the prevention of
injury. Extraorally administered PBMmay be effective for the
management of OM of the buccal mucosa, vestibule, and in-
ner epithelial surfaces of the lips which could be applied in
combination with an intraoral device.
Dermatitis
Radiation dermatitis occurs in the majority of patients with
locoregionally advanced HNC treated with RT.
The pathobiology of acute radiation dermatitis is com-
plex and partially overlaps that of OM. Irradiation of the
skin leads to direct tissue injury and inflammatory cell
recruitment, involving damage to epidermal basal cells
and connective tissue including endothelial cells and vas-
cular components [19]. Radiation-induced generation of
free radicals induces DNA injury and release of inflamma-
tory cytokines [mainly interleukin (IL)-1 and IL-6] [20,
21]. This process leads to the development of erythema,
edema, and possible ulceration. Late RT-induced changes
involving skin are characterized by the loss of follicular
structures, an increase in collagen and damage to elastic
fibers in the dermis, and a fragile epidermal covering [22].
Transforming growth factor beta (TGF-β) is considered to
play a central role in mediating RT-induced tissue fibrosis
[23–25].
Table 1 (continued)
Trismus Prophylacc: 
Radiotherapy: Apply PBM on 
pterygoid/TMJ region, at least 3 
mes a week, when high dose RT 
is given in that region 
(oropharyngeal and 
nasopharyngeal carcinoma for 
example).
Therapeuc:
Connue treatment from the day
of diagnosis at least 2 or 3 mes a
week
Extra-oral:
IR laser diodes or LED 
cluster 
750- 830 nm
20mW/cm2 - 80mW/cm2
Intra-oral:
630 - 680nm 
20mW - 200mW
Extra-oral:
3-6 J/cm2 laser diodes or LED 
cluster
Intra-oral:
3 J per point 
Extra-oral:
Bilaterally over the temporalis 
muscle, TMJ, masseter muscle, 
buccinator muscle *
Intra-oral:
Bilaterally, point over the 
region of 
pterygoids/pterygomandibular 
raphae (may be diﬃcult 
clinically) and other muscles of 
mascaon *
Osteonecrosis Therapeuc:
Connue treatment at least 2 or 3 
mes a week unl symptoms 
improve 
Daily treatment is recommended 
Combinaon with other 
medical/surgical treatment 
approaches may be needed.
Extra-oral:
IR laser diodes or LED 
cluster 
750- 830 nm
20mW/cm2 - 80mW/cm2
Intra-oral:
630 - 680nm 
20mW - 200mW
Extra-oral:
6 J/cm2 laser diodes or LED 
cluster
Intra-oral:
6 J per point 
Intra-oral:
5 or more points (1 cm apart) 
along lingual and buccal aspects 
of maxilla and / or mandible 
depending on site and size of 
region aﬀected *
Head and neck 
lymphedema
Therapeuc:
Connue treatment at least 2 or 3 
mes a week unl symptoms 
improve 
Extra-oral:
IR laser diodes or LED 
cluster 
750- 830 nm
20mW/cm2 - 80mW/cm2
Extra-oral:
3 J/cm2 laser diodes or LED 
cluster
Extra-oral:
Treat edematous area over the 
neck or surgical site if any, also 
targeng regional lymphac 
chain*
Voice/speech 
alteraons (due 
to local 
inﬂammaon)
Therapeuc:
Connue treatment from the day 
paent complains of diﬃculty 
speaking, at least 2 or 3 mes a 
week even if symptoms are not 
improving dramacally**
Intra-oral:
780nm - 830nm 
50mW - 200mW 
Intra-oral:
3 J/cm2per point
Extra-oral : on larynx area, 
wavelength 750-830 nm
IR laser diodes or LED cluster 
20mW/cm2 - 80mW/cm2
Intra-oral:
Towards the anterior 
oropharynx over the dorsum of 
tongue (avoid gag reﬂex, do not 
touch any so ssues including 
dorsal tongue). Paent may 
gently close the mouth during 
the procedure to reduce gag 
reﬂex
These protocols are based on evidence derived from the literature (mainly derived frommucositis studies) and expert opinion and are intended to provide
clinical guidance and to serve as a starting point for research. LED cluster probe dose has been expressed in J/cm2, and single point laser dose has been
expressed in joules per point. For LED cluster probes, treatment time (s) = dose (J/cm2) / power density (W/cm2). For single-point laser probes, treatment
time (s) = dose (J) / laser power (W)
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The severity of skin reactions is dependent on the total
radiation dose, the dose per fraction, the overall treatment
time, beam type and energy, the surface area of the skin ex-
posed to radiation, the use of combined chemoradiotherapy
with or without targeted therapies, and individual risk factors
[20]. The severity of acute reactions has been shown to predict
late effects. Radiation dermatitis impacts adversely on
cosmesis and function and reduces QoL, especially in patients
who develop secondarily infected dermatitis [19].
Patients with head and neck squamous cell carcinoma
(HNSCC) treated with an epithelial growth factor receptor
(EGFR) inhibitor may develop an acneiform skin rash in ad-
dition to radiation dermatitis [17, 22].
Based on the effects of PBM on the epidermis and dermis
(reduced inflammation and improved wound healing), and on
the shared similarities in pathobiology with OM, it seems
reasonable to assume that PBM may reduce the prevalence
and/or severity of radiation dermatitis [26–28].
A study in pigs suggested that multiwavelength PBM ame-
liorated the development of late radiation damage to the skin
[29]. DeLand et al. [30] reported that LED treatments imme-
diately after intensity-modulated radiation therapy (IMRT) re-
duced the incidence of radiation dermatitis in patients with
breast cancer. However, Fife et al. [31] were not able to repro-
duce these results, although unfortunately, they did not specify
important parameters such as irradiation time and size of area
treated.
A case series report described promising results for PBM
treatment at a NIR wavelength (970 nm) in patients with
EGFR inhibitor-induced facial rash [32].
Dysphagia
Acute and chronic dysphagia and odynophagia are common
in HNC patients, due to cancer following oropharyngeal/
laryngeal surgery and in those treated with RT or CRT [33,
34]. Dysphagia can be due to anatomical, mechanical, or neu-
rological changes affecting any structure from the lips to the
gastric cardia [35].
Dysphagia associated with RTor CRT has a complex path-
ogenesis, involving acute inflammation, edema, and fibrosis,
with consequent neurological and muscular injury that may
result in generalized weakness and a lack of muscle coordina-
tion while swallowing [34, 36, 37]. Excessive fibrosis results
in a loss of elasticity that may contribute to chronic dysphagia
[38, 39]. In addition, hyposalivation may contribute to dys-
phagia following RT [3]. Moreover, the duration of total par-
enteral nutrition (TPN) or tube feeding and resulting reduced
swallowing may affect the ability to return to safe, normal oral
intake, since inactivity will cause atrophy of the swallowing
muscles [40, 41]. Dysphagia negatively affects QoL [3, 42]
and may predispose to aspiration and life-threatening pulmo-
nary complications [43, 44].
IMRTand more recently volumetric-modulated arc therapy
(VMAT) have emerged as an effective technique to deliver the
full radiation dose to the tumor and regions at risk while re-
ducing exposure of surrounding healthy tissues. Eisbruch and
coworkers [45] identified dysphagia/aspiration-related struc-
tures (DARS) as susceptible to damage during IMRT. In par-
ticular, damage to the tongue base, pharyngeal constrictors,
the larynx, and the autonomic neural plexus was found to be
crucial in the development of post-RT dysphagia. Studies con-
firmed that reducing the radiation dose to DARS decreases
dysphagia risk [46–49]
In addition, preventive swallowing exercises in the pre-
treatment setting had promising results on preserving
(pharyngeal) swallowing function [48–50].
One study reported a lower incidence of severe OM and
mucositis affecting the throat (contributing to acute dyspha-
gia) when six predetermined oral sites were exposed to PBM
prior to and during RT [51]. In this study, dysphagia was
scored indirectly by assessing the need for TPN. Given the
ability of PBM to prevent and ameliorate inflammation and
pain associated with OM, and potential to control exuberant
fibrosis [52], PBM delivered to the DARS structures may
have a potential role in the management of acute and chronic
dysphagia. This requires further investigation.
Hyposalivation and xerostomia
Another significant complication of RT to the head and neck
region is hyposalivation, and its related complaint of
xerostomia (subjective oral dryness). For all head and neck
radiation regimens pooled, nearly all patients suffered from
xerostomia as a result of RT [53].
Irradiation of the salivary glands results in loss of gland
function, beginning early in the course of RT [54] and has
been shown to induce apoptosis in parotid glands in a dose-
dependent manner. This process is p53-dependent [55].
Saliva plays an important role in maintaining mucosal in-
tegrity, promoting oral wound healing, taste perception, for-
mation of food bolus, initiation of food ingestion, swallowing,
and speech [56]. Alterations in the oral microbiome, reduced
oral clearance, changes in saliva composition (e.g., decreased
buffer capacity, pH, immunoglobulin concentrations,
defensins), and dietary changes may increase the risk for mu-
cosal infections and rapidly progressing dental demineraliza-
tion and caries [57]. A substantial decrease in salivary func-
tion has a significant impact on QoL and results in an in-
creased burden of long-term dental care and nutrition [58–60].
There can be a modest improvement in xerostomia a few
months after RT, suggesting that an adaptation or compensa-
tory function of nonirradiated salivary glands or recovery of
some of the function occurs. However, most patients have
persisting oral dryness for the rest of their life, even when
3D conformal radiotherapy and IMRT is used. With IMRT
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preserving more of the major salivary glands, long-term oral
dryness may be reduced, but a significant proportion of pa-
tients still experience xerostomia [61].
The li terature on PBM for the management of
hyposalivation is limited. In a study involving a variety of
noncancer patients with xerostomia, PBM was applied daily:
extraorally to the parotid and submandibular glands and
intraorally on the sublingual glands. A gradual increase in
the stimulated salivary flow was found after PBM compared
to controls [62]. Similar results in noncancer patients were
reported by Vidović et al. [63]. Animal studies have shown
an increase in the number of duct epithelial cell mitoses and
stimulation to protein synthesis in submandibular glands fol-
lowing PBM [64, 65]. Similarly, a study reported the use of
PBM to increase salivary flow rate and amylase activity in rat
parotid glands [66]. These authors also performed a study in
HNC patients and reported that PBM given concurrently with
RT could prevent hyposalivation and xerostomia and had an
impact on the composition of saliva [67]. Less severe
xerostomia was also reported following PBM in HSCT recip-
ients [68] and in patients treated with chemotherapy for solid
tumors [69]. Increased salivary flow was observed in HNC
patients treated with RT [70]. A recent study performed in
HNC patients at least 6 months following conventional RT
found no improvement of hyposalivation and xerostomia,
likely due to irreversible acinar atrophy and fibrosis [71].
These results point to the potential use of PBM for preven-
tion of hyposalivation/xerostomia; it may also show efficacy
for the treatment of hyposalivation when there is residual
gland function following current RT modalities.
Taste alterations
Taste is one of the five senses and interacts with smell, touch,
and other physiological cues to affect the wider perception of
flavor. Disturbed taste (dysgeusia) is complex and includes
difficulties with smell and touch resulting in reduced food
interest and affecting appetite and QoL. Taste function is the
perception derived when foodmolecules stimulate taste recep-
tors of the tongue, soft palate, and the oropharyngeal region to
perceive basic taste qualities (sweet, sour, salty, bitter, and
umami), which can be measured via standardized methods
[72].
The prevalence of dysgeusia is estimated to be 66.5 %
following RT alone and 76.0 % after CRT; approximately
15% of patients continued to experience dysgeusia after treat-
ment [73]. Ohrn and colleagues reported that the severity of
taste alterations assessed by patients was correlated with the
cumulative RT dose [74].
The mechanisms of dysgeusia during cancer therapy are
not well understood; however, it is believed that CT and RT
cause dysgeusia by destroying rapidly dividing taste bud cells
and olfactory receptor cells [73]. Direct neurologic toxicity
may also be involved, as taste recovery lags epithelial recov-
ery and may continue indefinitely [75]. Hyposalivation may
also have a significant contribution. The presence of the ante-
rior part of the tongue in the radiation field may be predictive
of taste disturbances [76].
Altered taste significantly affects overall QoL andmay lead
to energy and nutrient deficiencies and related complications
that may lead to weight loss [3, 73]. Management options to
decrease the prevalence and severity of taste problems are
inadequate [75].
A pilot study reported that PBM administered to taste buds
may ameliorate neurologically mediated burning mouth syn-
drome symptoms including taste alterations [77], but to our
knowledge, there are no published studies on PBM for the
management of taste problems in cancer patients. Whether
PBM has any efficacy in the management of dysgeusia in
patients treated for HNC remains to be explored.
Trismus
Trismus refers to reduced opening of the jaws that may be
caused by spasm of the muscles of mastication, fibrosis in
masticatory muscles, and temporomandibular joint disorders,
which generally refers to mouth opening of less than 40 or less
than 20 mm, whereas less restrictive classifications also have
been used [78].
The prevalence of trismus is estimated to be 25 % follow-
ing conventional RT, 5 % following IMRT, and 31 % for CRT
[79]. Patients may have limitations in jaw opening associated
with tumor invasion of the masticatory muscles or the tempo-
romandibular joint, or may develop trismus following RT to
these structures [78, 80]. Cumulative radiation doses above
60 Gy are more likely to cause trismus [81], while the inclu-
sion of the lateral pterygoid muscles in the high-dose fields
appears to be the most decisive factor [82]. Trismus due to RT,
typically develops 3–6 months post-RT associated with fibro-
sis and frequently becomes a lifelong problem [80, 83].
Studies have demonstrated that fibrosis is an important
initial event in RT-induced trismus. Additionally, there may
be scar tissue from surgery, nerve damage, or a combination of
these factors [80]. Mandibular hypomobility ultimately results
in muscle contraction and potentially temporomandibular
joint dysfunction [79].
Trismus and orofacial pain interfering with function may
have significant health implications including reduced nutri-
tional intake, difficulty speaking, compromised oral health,
and poor QoL [84]. Aside from avoiding RT to the mastica-
tory structures, early interventions (e.g., mouth opening exer-
cises) are indicated to prevent or minimize trismus [48, 85,
86].
Concerningmuscle spasms following oral surgery, a reduc-
tion was found in several studies using PBM [87, 88]. To our
knowledge, PBM to prevent or reduce the severity of RT-
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induced trismus in HNC patients has not been reported. The
evidence for PBM to reduce fibrosis and promote muscle re-
generation forms the main rationale for a potential clinical
benefit and justifies further study.
Soft tissue necrosis and osteoradionecrosis
Soft tissue and/or osteoradionecrosis (ORN) may occur as a
consequence of RT. ORN is a process of radiation-induced
vascular occlusion leading to loss of osteocytes and bone ne-
crosis following RT [89]. The incidence of ORN has declined
with proper pretreatment dental care and advances in RT; in
conventional RT, mandibular ORN prevalence ranges from 5
to 15 %. More recently, in the era of IMRT, less than 5 % of
patients are affected [60, 80, 90].
The pathogenesis of ORN is not completely understood. It
has been proposed that ORN occurs following a radiation-
induced fibroatrophic process, including free radical forma-
tion, endothelial dysfunction, inflammation, microvascular
thrombosis, fibrosis and remodeling, and finally bone and
tissue necrosis [91]. Common triggers of necrosis are inflam-
matory dental disease, trauma to soft tissue, and dental surgi-
cal procedures in sites of high-dose radiation exposure to
bone. Dental surgery after RT is considered a critical risk
factor for ORN, but ORN can also arise due to periodontal
disease, trauma or spontaneously [92–94]. Prevention of ORN
is mainly based on extractions of compromised teeth before
RT and adequate dental care and prevention during and fol-
lowing cancer therapy [1, 89].
PBM has a biostimulatory effect on irradiated rat bone
when applied before and during RT [95], and similar results
were reported by El-Maghraby et al. [96]. In contrast, an
in vivo study found that PBM was not able to reverse RT-
induced bone damage [97]. To our knowledge, there are no
clinical studies on the effects of PBM for RT-induced jaw
osteonecrosis. However, multiple studies suggested a benefit
from PBM in the management of medication-related
osteonecrosis of the jaw (MRONJ) [98–101]. Vescovi et al.
proposed a prophylactic protocol including PBM for reducing
BRONJ incidence following tooth extractions [102].
Luomanen et al. reported about a successful treatment of a
patient with MRONJ using Nd:YAG laser [103]. A study in
a rodent wound healing model found evidence that both laser
and LED PBM were capable of stimulating angiogenesis
in vivo [104].
The possible role of PBM in the management of RT-
induced jaw osteonecrosis deserves further exploration.
Head and neck lymphedema
A commonly neglected late effect in patients treated for HNC
is secondary lymphedema [105], although this complication
may be reduced with IMRT. Patients may develop
lymphedema externally, on the face and neck, and/or internal-
ly involving the larynx and pharynx. External lymphedema
may have a profound effect on appearance and body image
[106], whereas internal lymphedema may impact breathing,
contribute to dysphagia and trismus, and may affect speech
[107].
In a single center study on 81 HNC patients, 75 % had
lymphedema. Of those, 10 % had external, 39 % had internal,
and 51 % had both types of lymphedema [107]. Individuals
with pharyngeal carcinoma were at highest risk [108].
Lymphedema typically develops 2–6 months after the com-
pletion of RTandmay resolve spontaneously in some patients,
but not in all. Assessment and measurement of head and neck
lymphedema remains challenging [109].
Lymphedema is initiated by disruption of lymphatic struc-
tures by surgery, RT or both, resulting in the accumulation of
lymph fluid in the interstitial tissues. This leads to infiltration
of inflammatory cells and, because of the lymphatic dysfunc-
tion, cytokines and chemokines remain in the tissue and re-
cruit additional inflammatory cells from the circulation. This
ongoing inflammatory response results in additional soft tis-
sue damage and fibrosis, which further adversely affects lym-
phatic function [110].
PBM has been identified as a potential treatment for post-
m a s t e c t o m y l ym p h e d em a , a s i t s t i m u l a t e s
lymphangiogenesis, enhances lymphatic motility, and reduces
lymphostatic fibrosis [111]. Patients received additional ben-
efits from PBM when used in conjunction with standard
lymphedema treatment [112]. Systematic reviews found evi-
dence suggesting that PBM reduced limb volume in patients
with lymphedema following treatment for breast cancer
[113–115]. It was concluded that future research should be
performed comparing PBM with standard practices and to
establish the duration of light application, number of treatment
sessions, energy settings, power density, and dose. In addition,
longer follow-up was considered necessary [114]. Lee and
coworkers proposed that PBM may also have a role in the
management of lymphedema associated with HNC [116].
Voice and speech alterations
Voice and speech are important communication tools and
form part of a person’s identity and personality. Voice quality
mainly depends on the movement and characteristics of the
vocal cords, and speech on the resonance characteristics of the
vocal tract. Speech is based on the volitional coordinated
movements of the articulator structures and can be affected
by any alteration in muscle or tissue properties of these struc-
tures. Although voice and speech dysfunctions significantly
affect QoL, these complications have received little attention
and are likely underreported in efforts to preserve organ func-
tion after cancer therapy [117–119].
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Currently, there is limited information on the prevalence of
speech and voice dysfunction in advanced HNC patients treat-
ed with RT or CRT. Prospective studies are needed, including
baselinemeasurements and standardizedmultidimensional as-
sessment of functional aspects of voice and speech [118].
The etiology of voice and speech problems resembles that
of dysphagia and may include neuromuscular weakness as a
result of tumor invasion. Dependent on the dose tolerance of
the critical organs involved, CRT-induced voice and/or speech
dysfunction can result from mucositis of the soft palate,
tongue and laryngeal soft tissues, edema, fibrosis, or atrophy
of the vocal folds, pharyngeal and oral tissues, and altered
saliva or hyposalivation [120–122].
New RT delivery techniques designed to spare these struc-
tures may prevent functional impairment.
A study using an animal model of reflux laryngitis (a con-
dition including hoarseness, voice fatigue, globus, chronic
cough, throat pain, and dysphagia) suggested that the anti-
inflammatory effects of PBM may play in the management
of this condition [123].
We are not aware of any studies on the effect of PBM on the
quality of speech and voice in HNC patients. Since PBMmay
preserve function of the anatomical structures involved by its
anti-inflammatory effects and may have indirect benefits by
stimulating the salivary flow, future studies are warranted.
Conclusion
Acute and chronic complications induced by RT and CRT in
patients with HNC represent a significant clinical challenge [1].
There are similarities with respect to pathophysiology across
different complications, and patients may suffer from multiple
concurrent and interrelated problems [13]. There is anecdotal
evidence suggesting that the inflammation associated with
acute complications is a harbinger for chronic complications.
This observation suggests that preventive approaches starting
before, and in the early phases of treatment with RT and CRT,
may not only reduce the risk for developing acute problems but
may also have an impact on the risk for late complications.
PBM has shown effectiveness in the management of OM
and elicits several potentially beneficial effects, including re-
duction of inflammation and pain, promotion of tissue repair,
reduction of fibrosis, and protection and regeneration of
nerves. Therefore, there is a clear motivation for studies on
the application of PBM for the prevention and treatment of a
broad range of acute and chronic complications associated
with RT or CRT in HNC patients.
The purpose of this article is to serve as a basis for estab-
lishing a platform for facilitating future collaborations among
clinicians and researchers, in order to create firm scientific
evidence for the use of PBM in patients with HNC. PBM
protocols should be administered using parameters that are
likely to affect the anatomic structures at risk. The parameters
(including the wavelengths) we have proposed are largely
based on evidence derived from studies using PBM for the
management of OM (typically 633–685 or 780–830 nm).
However, trials directed to other (non-head and neck) indica-
tions for the use of PBM suggest that a broader range of
wavelengths (590–1064 nm) has efficacy for healing and for
reducing inflammation and pain. Future investigations should
be conducted to better define optimal PBM parameters for
each of the complications of HNC treatment. LED specifics
need to be carefully matched to PBM using lasers when con-
sidering LED arrays and using them clinically. In addition, the
ideal timing and frequency of PBM administration should be
determined, as well as how long PBM should be continued
following the completion of cancer treatment. PBM parame-
ters should be reported in detail (discussed in part 1) and
validated outcome measures must be identified and employed
to assess the effect of prophylaxis and therapy, from the time
of diagnosis through active treatment and survival.
Despite the potential benefits and plausible safety of PBM for
supportive care in HNC patients, vigilance remains warranted.
While the reported results of in vitro studies of PBM on malig-
nant cells vary, and clinical reports have shown little or no ad-
verse reactions, there is a paucity of robust data regarding poten-
tial protection and promotion of tumor. Studies should be also
directed to the potential beneficial effects of PBM by enhancing
the efficacy of (C)RT or immunologic antitumor reactivity.
Investigations on the efficacy of PBM in the management
of side effects of HNC treatment should be conducted. It is
imperative that such studies include elucidating the effects of
PBM on oncology treatment outcomes.
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